The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials-Reference-Cited by-同舟云学术

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials

Published:2022-07 Issue:7 Volume:36 Page:771-783
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Doty Erin G.^ORCID,Hauck Paula M.,Krege John H.,Komori Mika,Hake Ann M.,Dong Yan,Lipton Richard B.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-022-00928-y.pdf

Reference22 articles.

1. Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action—review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.

2. Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788–801.

3. Doty EG, Krege JH, Jin L, et al. Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019;39(12):1569–76.

4. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–904.

5. Smith T, Krege JH, Rathmann SS, et al. Improvement in function after lasmiditan treatment: Post hoc analysis of data from phase 3 studies. Neurol Ther. 2020;9(2):459–71.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside;Nature Reviews Neurology;2023-07-12

2. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-07

3. Lasmiditan-related CNS AEs more likely if pain-free at 2h;Reactions Weekly;2022-07